(Q38631018)

4 September 2017

Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options (English)

1 reference

4 September 2017

Dimitri P Mikhailidis

series ordinal

3

object named as

Dimitri P Mikhailidis

1 reference

4 September 2017

2

Maciej Banach

1 reference

4 September 2017

1

Maria-Corina Serban

1 reference

PubMed ID

26559810

4 September 2017

language of work or name

English

0 references

publication date

11 November 2015

1 reference

Expert Opinion on Pharmacotherapy

4 September 2017

1 reference

4 September 2017

17

1 reference

4 September 2017

3

1 reference

4 September 2017

369-380

1 reference

Nicotinic acid/laropiprant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemia

4 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Lipid-lowering therapy in older persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Persistence with statin therapy in Hungary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Comparison of Application of the ACC/AHA Guidelines, Adult Treatment Panel III Guidelines, and European Society of Cardiology Guidelines for Cardiovascular Disease Prevention in a European Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Application of new guidelines for the primary prevention of atherosclerotic cardiovascular disease in a Korean population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Application of new cholesterol guidelines to a population-based sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Lipid-lowering therapies and achievement of LDL-cholesterol targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Evolving targets for lipid-modifying therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Safety and efficacy of ezetimibe: A meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

An international model to predict recurrent cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Simvastatin with or without ezetimibe in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Extended-release niacin or ezetimibe and carotid intima-media thickness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Statins and new-onset diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Lipids, blood pressure and kidney update 2014

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Atherosclerosis: Recent trials, new targets and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug E

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

The role of fibrate treatment in dyslipidemia: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Triglycerides and the Risk of Coronary Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

High-density lipoprotein cholesterol, a protective or a risk factor for developing coronary heart disease? Tehran Lipid and Glucose Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Defining the Safety of Anacetrapib, a CETP Inhibitor, in Patients at High Risk for Coronary Heart Disease: the DEFINE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

PCSK9 inhibition - a novel mechanism to treat lipid disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS S

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

PCSK9 inhibition in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Antihyperlipidemic therapies targeting PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Targeting PCSK9 for therapeutic gains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin + ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Using the concept of ideal cardiovascular health to measure population health: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1118055

10.1517/14656566.2016.1118055

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference

PubMed ID

26559810